These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 36682032)

  • 1. Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis.
    Jin Q; Fu L; Yang H; Chen X; Lin S; Huang Z; Gao B; Tian X; Jiang W; Shu X; Lu X; Wang G; Peng Q
    J Intern Med; 2023 Apr; 293(4):494-507. PubMed ID: 36682032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
    Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
    Front Immunol; 2022; 13():845988. PubMed ID: 35320936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic change of lymphocytes associated with short-term prognosis in anti-MDA5-positive dermatomyositis with interstitial lung disease: a multicenter retrospective study.
    Tian Y; He P; Ren L; Xin H; Xi B; Zou R; Zhao Q; Yan X; Qiu X; Gao Y; Liu Y; Cao M; Jiang H; Chen B; Chen J; Cai H
    Clin Rheumatol; 2024 Nov; 43(11):3399-3408. PubMed ID: 39292419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease.
    Ren FP; Chen Q; Yao SS; Feng L; Xue XY; Zhao WC; Wang D; Zhao ZL; Gu SW; Li T; Shen YW; Gao L; Zang XL; Bao XY; Tong ZH
    BMC Pulm Med; 2023 Oct; 23(1):411. PubMed ID: 37898737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
    Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
    Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.
    Ji Q; Pan W; Zhang D; Hou Y; Wang Z
    Front Immunol; 2023; 14():1237209. PubMed ID: 38098481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypouricemia as a novel predictor of mortality in anti-MDA5 positive dermatomyositis patients with ILD: A retrospective cohort study.
    Liu H; Chen B; Guo Y; Liu H; Ran J; Liu R; Yin G; Xie Q
    Respir Med; 2024 Feb; 222():107530. PubMed ID: 38228214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y; Fu Q; Wang R; Guo Q; Bao C
    J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical characteristics and prognostic factors of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis associated interstitial lung disease].
    Zou RY; Zhao Q; Tian YQ; Yan X; Qiu XH; Gao YJ; Liu Y; Huang M; Cao M; Dai JH; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Aug; 46(8):781-790. PubMed ID: 37536988
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy.
    Ge Y; Li S; Tian X; He L; Lu X; Wang G
    Clin Rheumatol; 2021 Jun; 40(6):2311-2317. PubMed ID: 33411136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk.
    Lv C; You H; Xu L; Wang L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Zhang M; Tan W
    J Rheumatol; 2023 Feb; 50(2):219-226. PubMed ID: 35705235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.
    Xu Y; Yang CS; Li YJ; Liu XD; Wang JN; Zhao Q; Xiao WG; Yang PT
    Clin Rheumatol; 2016 Jan; 35(1):113-6. PubMed ID: 26660480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of natural killer cell depletion in predicting progressive fibrosing interstitial lung disease in idiopathic inflammatory myopathies.
    Shao C; Xia N; Zhen Y; Zhang X; Yan N; Guo Q
    Front Immunol; 2024; 15():1404828. PubMed ID: 38745647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model.
    Wang L; Lv C; You H; Xu L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Liu J; Wang F; Zhang M; Tan W
    Front Immunol; 2024; 15():1286973. PubMed ID: 38361940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis.
    Shi Y; You H; Liu C; Qiu Y; Lv C; Zhu Y; Xu L; Wang F; Zhang M; Tan W
    Orphanet J Rare Dis; 2024 Apr; 19(1):170. PubMed ID: 38637830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
    Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
    Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.
    Li Y; Li Y; Wu J; Miao M; Gao X; Cai W; Shao M; Zhang X; Xu Y; Cong L; He J; Sun X
    J Immunol Res; 2020; 2020():2024869. PubMed ID: 33299896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
    Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
    Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
    Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
    Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.